Serum Aβ levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort

Molecular Medicine

Volumn 15, Issue 11-12, 2009, Pages 432-437

  Abdullah, Laila ^a   Luis, Cheryl ^a   Paris, Daniel ^a   Mouzon, Benoit ^a   Ait Ghezala, Ghania ^a   Keegan, Andrew P ^a   Wang, Duolao ^b   Crawford, Fiona ^a   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; CELECOXIB; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; COHORT ANALYSIS; DEMENTIA; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 73249123245     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00083     Document Type: Article

References (36)

1. Thompson PW, Lockhart A. (2009) Monitoring the amyloid beta-peptide in vivo: caveat emptor. Drug Discov. Today. 14:241-51.
2. Shaw LM, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65:403-13.
3. Leow AD, et al. (2009) Alzheimer's Disease Neuroimaging Initiative: a one-year follow up study using Tensor-Based Morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage. 2009, Jan 19 [Epub ahead of print].
4. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. (2006) Plasma Aβ(140) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5:655-60.
5. Graff-Radford NR, et al. (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64:354-62.
6. Schupf N, et al. (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 105:14052-7.
7. Kuo YM, et al. (2000) Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol. Med. 6:430-9.
8. Blasko I, et al. (2008) Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort. J. Psychiatr. Res. 42:946-55.
9. Abdullah L, et al. (2009) High serum Abeta and vascular risk factors in first- degree relatives of Alzheimer's disease patients. Mol. Med. 15:95-100.
10. Lopez OL, et al. (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology. 70:1664-71.
11. Sjögren M, Blennow K (2005) The link between cholesterol and Alzheimer's disease. World J. Biol. Psychiatry. 6:85-97.
12. Kivipelto M, et al. (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137:149-55.
13. Fujiwara Y, et al. (2003) Relationships between plasma beta-amyloid peptide 1-42 and atherosclerotic risk factors in community-based older populations. Gerontology. 49:374-9.
14. Sabbagh M, et al. (2004) Is there a characteristic lipid profile in Alzheimer's disease? J. Alzheimers Dis. 6:585-9.
15. ADAPT Research Group, et al. (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65:896-905.
16. Randolph C. (1998) Repeatable battery for the assessment of neuropsychological status manual. San Antonio: The Psychological Corporation.
17. Patton DE, et al. (2006) RBANS index discrepancies: base rates for older adults. Arch. Clin. Neuropsychol. 21:151-60.
18. Morris J, et al. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 39:1159-65.
19. Wechsler D. (1987) Wechsler Memory Scale-Revised. San Antonio: The Psychological Corporation.
20. Benton A, Sivan A, Hamsher K, Varney N, Spreen O. (1983) Judgment of Line Orientation: Form H. Lutz (FL): Psychological Assessment Resources, Inc.
21. Wechsler D. (1997) Wechsler Adult Intelligence Scale. 3rd ed. San Antonio: The Psychological Corporation.
22. Petersen RC, et al. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56:303-8.
23. McKhann G, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:939-44.
24. Petersen RC, Negash S (2008) Mild cognitive impairment: an overview. CNS Spectr. 13:45-53.
25. Petersen RC, et al. (2001) Current concepts in mild cognitive impairment. Arch. Neurol. 58:1985-92.
26. Whitwell JL, et al. (2007) Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch. Neurol. 64:1130-8.
27. ADAPT Research Group, et al. (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 68:1800-8.
28. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry. 80:13-7.
29. Forette F, et al. (2002) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162:2046-52.
30. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH (2009) Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 72:1727-34.
31. Rosenberg PB, et al. (2008) Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am. J. Geriatr. Psychiatry. 16:883-92.
32. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br. J. Clin. Pharmacol. 67:99-109.
33. 42- lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 70:2291-8.
34. Szekely CA, et al. (2008) NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology. 70:17-24
35. Breitner JC, et al. (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 72:1899-905.
36. Breitner JCS. (2008) Onset of Alzheimer's dementia occurs commonly without prior cognitive impairment: results from the Alzheimer's disease anti-inflammatory prevention trial (ADAPT). Alzheimers Dement. 4(4 Suppl 1):T130-1.